Scarica l'app Stockscreener
32.32
7.63%
-2.67
Dopo l'orario di chiusura:
31.97
-0.35
-1.08%
Precedente Chiudi:
$34.99
Aprire:
$33.53
Volume 24 ore:
1.08M
Relative Volume:
1.80
Capitalizzazione di mercato:
$1.89B
Reddito:
-
Utile/perdita netta:
$-146.66M
Rapporto P/E:
-11.74
EPS:
-2.7541
Flusso di cassa netto:
$-133.21M
1 W Prestazione:
-18.63%
1M Prestazione:
+6.42%
6M Prestazione:
-40.68%
1 anno Prestazione:
-45.22%
Intervallo 1D:
$30.81
$33.66
Intervallo di 1 settimana:
$30.81
$38.95
Portata 52W:
$29.26
$63.50
Apogee Therapeutics Inc Stock (APGE) Company Profile
Nome
Apogee Therapeutics Inc
Settore
Industria
Telefono
650-394-5230
Indirizzo
221 CRESCENT ST., WALTHAM
Confronta APGE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
APGE
Apogee Therapeutics Inc
|
32.32 | 1.89B | 0 | -146.66M | -133.21M | -2.7541 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 125.40B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 65.79B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 35.18B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 32.67B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 26.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Apogee Therapeutics Inc Stock (APGE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-13 | Iniziato | Citigroup | Buy |
| 2024-11-25 | Iniziato | Canaccord Genuity | Buy |
| 2024-05-10 | Iniziato | BofA Securities | Buy |
| 2023-12-20 | Iniziato | BTIG Research | Buy |
| 2023-08-08 | Iniziato | Guggenheim | Buy |
| 2023-08-08 | Iniziato | Jefferies | Buy |
| 2023-08-08 | Iniziato | Stifel | Buy |
| 2023-08-08 | Iniziato | TD Cowen | Outperform |
| 2023-08-08 | Iniziato | Wedbush | Outperform |
Mostra tutto
Apogee Therapeutics Inc Borsa (APGE) Ultime notizie
Teacher Retirement System of Texas Purchases 1,848 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World
Swiss National Bank Raises Stock Position in Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World
Analysts Set Apogee Therapeutics, Inc. (NASDAQ:APGE) PT at $92.17 - Defense World
Is Apogee Therapeutics (APGE) Among the Best IPO Stocks to Buy in 2025? - Insider Monkey
(APGE) Trading Advice - news.stocktradersdaily.com
Charles Schwab Investment Management Inc. Sells 2,936 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World
12 Best IPO Stocks to Buy in 2025 - Insider Monkey
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Bank of New York Mellon Corp Decreases Position in Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World
May 16th Options Now Available For Apogee Therapeutics (APGE) - Nasdaq
(APGE) Trading Signals - Stock Traders Daily
Apogee Therapeutics (NASDAQ:APGE) Coverage Initiated at Citigroup - Defense World
Victory Capital Management Inc. Sells 123,296 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World
Apogee Therapeutics (NASDAQ:APGE) Trading Up 4.5%What's Next? - MarketBeat
Citigroup Initiates Coverage of Apogee Therapeutics (APGE) with Buy Recommendation - Nasdaq
Citigroup Initiates Apogee Therapeutics at Buy With $95 Price Target -March 13, 2025 at 07:14 am EDT - Marketscreener.com
Apogee Therapeutics initiated with a Buy at Citi - TipRanks
Zevra Therapeutics Inc (ZVRA) gets rating Resumed from Cantor Fitzgerald - Knox Daily
Apogee Therapeutics (NASDAQ:APGE) Given Outperform Rating at Wedbush - Defense World
Apogee Therapeutics signs manufacturing deal with Samsung Biologics By Investing.com - Investing.com Canada
Apogee Therapeutics signs manufacturing deal with Samsung Biologics - Investing.com India
Apogee Therapeutics IncEnters Master Services Agreement With Samsung Biologics - Marketscreener.com
TD Cowen reiterates buy on Apogee Therapeutics stock - Investing.com India
TD Cowen reiterates buy on Apogee Therapeutics stock By Investing.com - Investing.com UK
Strong Buy Recommendation for Apogee Therapeutics Driven by Promising Clinical Data and Strategic Pipeline Developments - TipRanks
Apogee Therapeutics' Investigational Atopic Dermatitis Potential Shows Strong Tolerability, Extended Half-Life in Early Trial - AOL
Apogee Therapeutics CEO Michael Henderson sells $301,511 in stock By Investing.com - Investing.com South Africa
Apogee Therapeutics CEO Michael Henderson sells $301,511 in stock - Investing.com
Apogee Therapeutics CMO Carl Dambkowski sells $48,463 in stock By Investing.com - Investing.com South Africa
Apogee Therapeutics CMO Carl Dambkowski sells $48,463 in stock - Investing.com India
Q1 EPS Estimates for Apogee Therapeutics Reduced by Wedbush - Defense World
New York State Common Retirement Fund Increases Position in Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World
Apogee Therapeutics (NASDAQ:APGE) Reaches New 1-Year Low After Earnings Miss - Defense World
Where are the Opportunities in (APGE) - news.stocktradersdaily.com
Optimistic Buy Rating for Apogee Therapeutics Driven by Promising Clinical Trial Developments - TipRanks
Apogee Therapeutics, Inc. (NASDAQ:APGE) Shares Sold by Handelsbanken Fonder AB - Defense World
Apogee Therapeutics (NASDAQ:APGE) Receives “Outperform” Rating from Wedbush - Defense World
Apogee Therapeutics Reports 2024 Financial Results and Pipeline Progress - TipRanks
APGEApogee Therapeutics Inc Latest Stock News & Market Updates - Stock Titan
Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2024 Financial Results - GlobeNewswire
Jefferies lifts Apogee Therapeutics stock target to $86, maintains buy - Investing.com India
Jefferies lifts Apogee Therapeutics stock target to $86, maintains buy By Investing.com - Investing.com South Africa
Apogee Therapeutics price target raised to $116 from $110 at Guggenheim - TipRanks
Apogee Therapeutics Reports Positive Phase 1 Results - TipRanks
Apogee Therapeutics, Inc. Announces Positive Interim Phase 1 Results from the APG990 Healthy Volunteer Trial, Unlocking Potential Maintenance Dosing Every Three and Six Months for APG990 - Marketscreener.com
Apogee Therapeutics Full-Year Loss Widens -March 03, 2025 at 06:56 am EST - Marketscreener.com
Apogee Therapeutics, Inc. SEC 10-K Report - TradingView
Apogee Therapeutics Announces Positive Interim Phase 1 Results From The APG990 Healthy Volunteer Trial - Marketscreener.com
Apogee Therapeutics Inc Azioni (APGE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apogee Therapeutics Inc Azioni (APGE) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Dambkowski Carl | Chief Medical Officer |
Mar 05 '25 |
Sale |
30.48 |
1,590 |
48,463 |
251,033 |
| HENDERSON MICHAEL THOMAS | Chief Executive Officer |
Mar 05 '25 |
Sale |
30.15 |
10,000 |
301,511 |
1,292,987 |
10.70%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):